Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

25 Jun 2024

Abstract excerpt

There is a paucity of comprehensive knowledge pertaining to the underlying mechanisms leading to gefitinib resistance in individuals diagnosed NSCLC harboring EGFR-sensitive mutations who inevitably develop resistance to gefitinib treatment within six months to one year. In our preceding investigations, we have noted a marked upregulation of IGFBP2 in the neoplastic tissues of NSCLC, predominantly in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Growth Hormone and Insulin-like Growth Factors
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38918360
DOI: 10.1038/s41419-024-06843-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancerPMID 38918360Read ↗

Identification of biomarkers, pathways and potential therapeutic targets for EGFR-TKI resistance in non-small-cell lung cancerSemantic proximity Read ↗

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

Systematic analysis of IGF2BP family members in non-small-cell lung cancer.Semantic proximity Read ↗

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLCSemantic proximity Read ↗

Different Roles of the Insulin-like Growth Factor (IGF) Axis in Non-small Cell Lung CancerSemantic proximity Read ↗

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLCSemantic proximity Read ↗

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cellsSemantic proximity Read ↗

The inhibitory effect of M2 macrophage-derived exosomes on gefitinib resistant lung adenocarcinoma cells through the MIF/TIMP1/CD74 axisSemantic proximity Read ↗

The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.Semantic proximity Read ↗

FGL1 Regulates Acquired Resistance to Gefitinib by Inhibiting Apoptosis in Non-small Cell Lung CancerSemantic proximity Read ↗

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLCSemantic proximity Read ↗

EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.